Stockscreener 앱 받기
123.36
0.02%
-0.03
시장 영업 전:
123.31
-0.05
-0.04%
전일 마감가:
$123.39
열려 있는:
$123.4
하루 거래량:
4.84M
Relative Volume:
2.76
시가총액:
$9.76B
수익:
-
순이익/손실:
$-450.07M
주가수익비율:
-20.36
EPS:
-6.0583
순현금흐름:
$-312.79M
1주 성능:
+0.01%
1개월 성능:
+20.59%
6개월 성능:
+21.84%
1년 성능:
+62.19%
1일 변동 폭
$123.30
$123.50
1주일 범위
$123.15
$123.57
52주 변동 폭
$71.13
$123.62
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
123.36 | 9.76B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Wells Fargo | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal - Streetwise Reports
AASTOCKS Financial NewsNuvalent, Inc. (NUVL) - AASTOCKS.com
GSK agrees to acquire Nuvalent, Inc. - Pennsylvania Business Report -
Halper Sadeh LLC is Investigating Whether DAN, NUVL, SUNE, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
GSK in talks to buy Nuvalent for more than $9 billion: FT - MSN
GSK To Acquire Nuvalent In Largest Deal In Over A Decade – Merger Arbitrage Mondays (NYSE:GSK) - Seeking Alpha
GSK buys Nuvalent for $10.6 billion in major cancer push - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Assessing the 3.96% Potential Upside Amidst Biotech Innovation - DirectorsTalk Interviews
Herbert Smith Freehills Kramer advises on the financing for GSK plc's US$10.6 billion acquisition of Nuvalent Inc. - Legal Desire Media and Insights
NUVL stock surges 39% premarket – why is GSK buying this Boston-based oncology company? - MSN
GSK to Acquire Nuvalent for $10.6 Billion - GuruFocus
The week in pharma: action, reaction and insight – week to June 12, 2026 - The Pharma Letter
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent - GuruFocus
Patent cliff predators: GSK acquires Nuvalent for $10.6 billion - MSN
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK - MSN
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? - TradingView
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $124 to $126 - Moomoo
Nuvalent (NUVL) CDO sells 20,000 shares, exercises options - Stock Titan
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors - Seeking Alpha
GSK To Acquire Nuvalent for $10.6 Bn - DCAT Value Chain Insights
GSK to acquire Nuvalent for $10.6bn ahead of patent cliff - EMJ
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - MSN
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - Investing.com
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - MarketBeat
Slaughters, Davis Polk, Ropes line up on GSK’s $10.6bn biotech buy - Non-Billable
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - TradingView
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) - Yahoo Finance UK
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 - CHEManager
GSK Acquires Nuvalent To Maximise Cancer Treatments - Healthcare Digital
GSK Announces Record $10.6 Billion Acquisition of Nuvalent to Rebuild Oncology Portfolio - IndexBox
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal By Reuters - Investing.com
Investigation launched into Nuvalent's $10.6B deal with GSK over possible board breaches and unfair terms - Pluang
GSK to acquire Nuvalent for $10.6 billion in cash deal - scanx.trade
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - BioSpace
GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares - MSN
GSK makes $10.6B move for Nuvalent to boost cancer pipeline - MSN
GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn - MSN
GSK to buy Nuvalent for $10.6 billion in oncology push - MSN
GSK plc to pursue cash tender offer for Nuvalent (NASDAQ: NUVL) - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments - Genetic Engineering and Biotechnology News
GSK’s US$10.6b Nuvalent Purchase Recasts Oncology And Future Revenue Mix - simplywall.st
GSK Enters Agreement to Acquire Nuvalent Inc June 10, 2026 - James Sharp & Co.
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc.NUVL - Business Wire
GSK advances oncology efforts with $10.6bn Nuvalent acquisition - European Pharmaceutical Review
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push - PharmTech.com
GSK to Acquire U.S. Biotech Firm Nuvalent for $10.6bn in Largest Pharma Deal in a Decade - Tekedia
Bernstein reiterates Nuvalent stock rating on GSK acquisition - Investing.com
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
GSK's $10.6B Nuvalent buy gains analyst backing for lung cancer growth amid HIV patent worries - Pluang
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Jun 09 '26 |
Sale |
122.81 |
20,000 |
2,456,200 |
58,117 |
| Porter James Richard | President and CEO |
Jun 08 '26 |
Option Exercise |
18.93 |
30,000 |
567,900 |
354,879 |
| Porter James Richard | President and CEO |
Jun 08 '26 |
Sale |
88.53 |
30,000 |
2,656,004 |
324,879 |
2.60%
0.94%
자본화:
|
볼륨(24시간):